Uncategorized
Congressional Budget Office releases cost estimate for FDA Reauthorization Act of 2017
The Congressional Budget Office released its cost estimate for the FDA Reauthorization Act of 2017, noting the bill would increase net discretionary spending by about $740 million during the 2017 to 2022 period if appropriation actions are consistent with the bill. Although the implementation would require increased funding for a variety of FDA activities, the CBO reported most of the increase in FDA spending would be offset by additional fees collected under the bill and used to reduce the need for discretionary appropriations.